Duchenne Muscular Dystrophy Community, News and Tools

Our Clinical Trials Hub makes it easier to find, explore, and compare Duchenne clinical trials. With AI-assisted updates and multilingual access, reliable clinical trial information is always within reach.

10 LANGUAGES

Worldwide Access

AI-POWERED

Always Updated

SMART INSIGHTS

Research Statistics

With a mission to help treat Duchenne muscular dystrophy

Many people in the world do not know what Duchenne muscular dystrophy is. Because only one in every 5,000 boys gets this disease. However, families and their surroundings whose children struggle with this disease have to live with the stress of this disease every day. We call them DMD Warriors.

DMDWarrior.com was established to raise awareness of this disease worldwide, facilitate access to treatments, and ensure that treatment costs are affordable. Together, we will keep fighting for better treatments and access for everyone with Duchenne.

Duchenne muscular dystrophy awareness motocross rider performing a jump in autumn

What is our purpose?

One in every 5,000 children worldwide is born with Duchenne muscular dystrophy (DMD), and many families do not realize that their child has the disease until they are 3 or 4 years old. EMA and FDA-approved DMD treatments are often too expensive for families to afford. Our goal is to reduce treatment costs and ensure that these treatments are covered by governments.

Home

Ease of Access to Treatments

In many countries, DMD treatments are not available, and families incur huge costs for travel abroad.

Home

Reducing Treatment Costs

Treatments for DMD are very expensive, and it is nearly impossible for families to cover these costs themselves.

Home

Raising Awareness

We do not want any child to die. If you also want to find a solution to this situation, follow us on social media.

DMD Reach

DMDWarrior has built a global digital community dedicated exclusively to Duchenne muscular dystrophy (DMD), connecting families with clear, accessible and up-to-date information in 10 languages. Our independent platform reaches families, caregivers and the wider DMD community across the world.

10+
Languages

One Global DMD Community

86%
World Population

Reached In Local Languages

380K+
Unique Visitors

Engaging With DMDWarrior

2.05M+
Total Impressions

Across Our Global Platform

Discover our tools now!

Home

Find Duchenne clinical trials faster with smart search, filters, and easy-to-use trial information!

Home

Analyze DMD exon deletions and discover approved and potential treatments for your mutation profile.

Home

Our Android and iOS apps are now in testing and will be released soon with trusted DMD resources soon.

Duchenne News & Articles

Entrada Therapeutics ENTR-601-45: Early Exon 45 Skipping Study Shows Increased Dystrophin Production

Entrada Therapeutics has announced positive initial results from its Exon 45 Skipping Study, ELEVATE-45-201, evaluating ENTR-601-45 in people with Duchenne muscular dystrophy (Duchenne). The...

Entrada Therapeutics Advances ENTR-601-44 to 18 mg/kg in Its Duchenne Exon 44 Skipping Study

Entrada Therapeutics has received clearance to test the highest dose in its Exon 44 Skipping Study for Duchenne muscular dystrophy (DMD). The independent Data...

Sapreme Therapeutics Reports Strong Preclinical Dystrophin Restoration With SPM-2551 in Duchenne

Sapreme Therapeutics has announced promising preclinical results for SPM-2551, an experimental treatment for Duchenne muscular dystrophy (Duchenne) that uses exon-skipping technology and RNA-based medicines,...

Deramiocel Shows Positive 24-Month HOPE-3 Results in Duchenne

Capricor Therapeutics has reported new results from the HOPE-3 study evaluating Deramiocel in people with Duchenne muscular dystrophy (DMD). The 24-month open-label extension data...

Ractigen Therapeutics Reports Positive First-in-Human Data for RAG-18 in Duchenne

Ractigen Therapeutics has presented positive first-in-human data for RAG-18 (NCT07282652), an investigational treatment for Duchenne muscular dystrophy (Duchenne) that uses small activating RNA (saRNA)...